Dexcom Ventures

Dexcom Ventures Dexcom Ventures launched in February 2021 as the CVC arm of Dexcom, the $10B+ market cap leader in continuous glucose monitoring (CGM). Led by Jason Halac (MD) with over 20 years of combined team experience, the fund has made 9 targeted investments in biosensing technology and data-driven healthcare adjacent to Dexcom's CGM core. The portfolio is highly focused: Beta Bionics (iLet Bionic Pancreas), Signos (AI glucose optimization app), and Nutromics (continuous molecular monitori